These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 35517783)

  • 1. BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis.
    Herrmann FE; Hesslinger C; Wollin L; Nickolaus P
    Front Pharmacol; 2022; 13():838449. PubMed ID: 35517783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BI 1015550: an investigational phosphodiesterase 4B (PDE4B) inhibitor for lung function decline in idiopathic pulmonary fibrosis (IPF).
    Sgalla G; Simonetti J; Cortese S; Richeldi L
    Expert Opin Investig Drugs; 2023 Jan; 32(1):17-23. PubMed ID: 36693635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages.
    Maier C; Ramming A; Bergmann C; Weinkam R; Kittan N; Schett G; Distler JHW; Beyer C
    Ann Rheum Dis; 2017 Jun; 76(6):1133-1141. PubMed ID: 28209630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis.
    Wollin L; Maillet I; Quesniaux V; Holweg A; Ryffel B
    J Pharmacol Exp Ther; 2014 May; 349(2):209-20. PubMed ID: 24556663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The unrecognized effects of phosphodiesterase 4 on epithelial cells in pulmonary inflammation.
    Konrad FM; Bury A; Schick MA; Ngamsri KC; Reutershan J
    PLoS One; 2015; 10(4):e0121725. PubMed ID: 25909327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases.
    Wittmann M; Helliwell PS
    Dermatol Ther (Heidelb); 2013 Jun; 3(1):1-15. PubMed ID: 23888251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multi-target antisense approach against PDE4 and PDE7 reduces smoke-induced lung inflammation in mice.
    Fortin M; D'Anjou H; Higgins ME; Gougeon J; Aubé P; Moktefi K; Mouissi S; Séguin S; Séguin R; Renzi PM; Paquet L; Ferrari N
    Respir Res; 2009 May; 10(1):39. PubMed ID: 19457265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphodiesterase 4 in inflammatory diseases: Effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4/CD271 complex.
    Schafer PH; Truzzi F; Parton A; Wu L; Kosek J; Zhang LH; Horan G; Saltari A; Quadri M; Lotti R; Marconi A; Pincelli C
    Cell Signal; 2016 Jul; 28(7):753-63. PubMed ID: 26806620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
    Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
    Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization.
    Tralau-Stewart CJ; Williamson RA; Nials AT; Gascoigne M; Dawson J; Hart GJ; Angell AD; Solanke YE; Lucas FS; Wiseman J; Ward P; Ranshaw LE; Knowles RG
    J Pharmacol Exp Ther; 2011 Apr; 337(1):145-54. PubMed ID: 21205923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages.
    Jin SL; Lan L; Zoudilova M; Conti M
    J Immunol; 2005 Aug; 175(3):1523-31. PubMed ID: 16034090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sappanone A: A natural PDE4 inhibitor with dual anti-inflammatory and antioxidant activities from the heartwood of Caesalpinia sappan L.
    Wang YZ; Wang YL; Che HJ; Jia YH; Wang HF; Zuo LF; Yang K; Li TT; Wang JX
    J Ethnopharmacol; 2023 Mar; 304():116020. PubMed ID: 36529254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice.
    Udalov S; Dumitrascu R; Pullamsetti SS; Al-tamari HM; Weissmann N; Ghofrani HA; Guenther A; Voswinckel R; Seeger W; Grimminger F; Schermuly RT
    BMC Pulm Med; 2010 May; 10():26. PubMed ID: 20444277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of ciclamilast, a new PDE 4 PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthma.
    Deng YM; Xie QM; Tang HF; Sun JG; Deng JF; Chen JQ; Yang SY
    Eur J Pharmacol; 2006 Oct; 547(1-3):125-35. PubMed ID: 16956605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis.
    Richeldi L; Azuma A; Cottin V; Hesslinger C; Stowasser S; Valenzuela C; Wijsenbeek MS; Zoz DF; Voss F; Maher TM;
    N Engl J Med; 2022 Jun; 386(23):2178-2187. PubMed ID: 35569036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors.
    Wollin L; Bundschuh DS; Wohlsen A; Marx D; Beume R
    Pulm Pharmacol Ther; 2006; 19(5):343-52. PubMed ID: 16257550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of inhibition of ovalbumin-induced bronchoconstriction in guinea pigs and in vitro inhibition of tumor necrosis factor-alpha formation with phosphodiesterase 4 (PDE4) selective inhibitors.
    Muise ES; Chute IC; Claveau D; Masson P; Boulet L; Tkalec L; Pon DJ; Girard Y; Frenette R; Mancini JA
    Biochem Pharmacol; 2002 Apr; 63(8):1527-35. PubMed ID: 11996895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphodiesterase 4 inhibition reduces lung fibrosis following targeted type II alveolar epithelial cell injury.
    Sisson TH; Christensen PJ; Muraki Y; Dils AJ; Chibucos L; Subbotina N; Tohyama K; Horowitz JC; Matsuo T; Bailie M; Nikam S; Hazama M
    Physiol Rep; 2018 Jun; 6(12):e13753. PubMed ID: 29952109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhalation: A means to explore and optimize nintedanib's pharmacokinetic/pharmacodynamic relationship.
    Epstein-Shochet G; Pham S; Beck S; Naiel S; Mekhael O; Revill S; Hayat A; Vierhout M; Bardestein-Wald B; Shitrit D; Ask K; Montgomery AB; Kolb MR; Surber MW
    Pulm Pharmacol Ther; 2020 Aug; 63():101933. PubMed ID: 32750409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LPS-induced lung inflammation in marmoset monkeys - an acute model for anti-inflammatory drug testing.
    Seehase S; Lauenstein HD; Schlumbohm C; Switalla S; Neuhaus V; Förster C; Fieguth HG; Pfennig O; Fuchs E; Kaup FJ; Bleyer M; Hohlfeld JM; Braun A; Sewald K; Knauf S
    PLoS One; 2012; 7(8):e43709. PubMed ID: 22952743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.